A Phase 2, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of PRAX-114 in Participants With Post-Traumatic Stress Disorder
Latest Information Update: 05 Dec 2022
At a glance
- Drugs PRAX-114 (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- Sponsors Praxis Precision Medicines
- 28 Nov 2022 Status changed from active, no longer recruiting to discontinued as No longer developing for this indication.
- 20 Jul 2022 Status changed from recruiting to active, no longer recruiting.
- 28 Feb 2022 According to a Praxis Precision Medicines media release, this trial initiated in fourth quarter of 2021 and has started dosing participants.